Abbott Laboratories has added another United States product to the rapidly changing pulsed-field ablation market after the United States Food and Drug Administration approved its TactiFlex Duo Ablation Catheter, Sensor Enabled, for treatment of atrial fibrillation. The catheter can deliver pulsed-field ablation, radiofrequency energy or both, allowing electrophysiologists to switch energy source without changing the focal catheter.
The device’s strategy is notably different from the industry narrative that pulsed-field ablation will simply displace thermal energy. Abbott is effectively arguing that electrophysiologists may want both. Pulsed-field ablation provides rapid, non-thermal tissue-selective energy, while radiofrequency remains familiar and useful in anatomical situations or targets where thermal lesion creation is preferred.
Why has pulsed-field ablation changed the AFib device market so quickly?
Traditional catheter ablation commonly relies on radiofrequency energy or cryothermal energy to create lesions that interrupt abnormal electrical pathways. Those modalities work, but heat or freezing can injure nearby structures if energy delivery extends beyond the intended tissue.
Pulsed-field ablation uses brief high-voltage electrical pulses to induce irreversible electroporation in myocardial cells. Because different tissues have different susceptibility thresholds, the approach is designed to preferentially ablate cardiac tissue while reducing damage to surrounding structures such as the oesophagus or phrenic nerve.
That potential combination of speed and tissue selectivity has driven unusually rapid adoption. Medtronic, Boston Scientific, Johnson & Johnson and Abbott are all competing across the PFA ecosystem, transforming a field that only recently relied overwhelmingly on thermal ablation.
Abbott already markets its Volt PFA platform, meaning TactiFlex Duo is not its first entry. The latest catheter broadens the company’s proposition by adding a focal device that can move between energy sources while remaining integrated with Abbott’s EnSite X mapping environment.
What did the FlexPulse study show?
The FDA approval was supported by Abbott’s FlexPulse global investigational device exemption study. The prospective, single-arm multicentre trial treated 180 patients with symptomatic drug-refractory paroxysmal atrial fibrillation and achieved pulmonary-vein isolation in all enrolled participants. Operators were allowed to perform additional ablation beyond pulmonary-vein isolation when clinically appropriate, and about 37% of patients received such additional treatment.
The primary safety-event rate was 1.7%. The study reported no stroke or transient ischaemic attack, phrenic-nerve injury, oesophageal lesion, pulmonary-vein stenosis or device- or procedure-related death among the headline safety outcomes highlighted by Abbott.
At 12 months, 74.6% of patients met the trial’s composite primary effectiveness endpoint, which included recurrence, repeat procedures, escalation of antiarrhythmic medication and cardioversion. Freedom from documented atrial fibrillation, atrial flutter or atrial tachycardia was 77.4% using the study’s intensive monitoring approach and 92.6% when assessed through standard-of-care monitoring. Approximately 91.7% remained free from repeat ablation.
Why are the different efficacy percentages important?
Atrial fibrillation trials can produce markedly different recurrence rates depending on how aggressively researchers look for arrhythmia. Weekly transtelephonic monitoring can detect short, asymptomatic episodes that routine clinical follow-up might never identify.
That explains why Abbott reports both 77.4% freedom from documented arrhythmia under the stricter trial-monitoring structure and 92.6% under standard-of-care monitoring. Neither number is inherently misleading, but they answer somewhat different questions.
The stricter measurement is useful for scientific comparison because it reduces the chance that recurrent episodes go unnoticed. The standard-care figure may better approximate what many physicians and patients experience in routine follow-up, where recurrence is often identified through symptoms, scheduled monitoring or clinically indicated testing.
For commercial interpretation, the distinction also illustrates why headline success percentages across ablation systems should not be compared casually. Monitoring protocols, blanking periods, medication definitions and patient populations can create large apparent differences even when underlying treatment performance is similar.
What does dual energy add if PFA is already effective?
Pulmonary-vein isolation remains the foundation of most paroxysmal AF ablation, and pulsed-field systems can perform that task efficiently. More complicated atrial arrhythmias, repeat procedures and anatomical targets beyond the pulmonary veins can demand greater procedural flexibility.
FlexPulse required PFA for posterior left-atrial treatment and radiofrequency near coronary arteries in specified situations, illustrating how the two energy sources can be used differently within one procedure. Additional non-pulmonary-vein ablation occurred in more than one-third of patients.
For an electrophysiologist, the appeal is avoiding a forced choice between a PFA-only catheter and an RF-only focal catheter. If the physician encounters scar, an atypical target or an area where one energy source appears preferable, the same catheter can theoretically remain in place.
The counterargument is simplicity. Dedicated PFA systems have attracted physicians partly because they can make pulmonary-vein isolation fast and standardized. A device offering more options creates value only if those options improve outcomes or make challenging cases easier without adding complexity.
Can mapping integration become Abbott’s competitive advantage?
Abbott has built TactiFlex Duo around its broader electrophysiology ecosystem rather than treating the catheter as an isolated disposable. The device integrates with the EnSite X EP System, Advisor HD Grid X mapping catheter and intracardiac imaging tools, giving physicians a connected environment for mapping, visualization and therapy delivery.
The company has also developed a PFA Index intended to give real-time information about lesion creation. In a retrospective subset of FlexPulse patients, workflows meeting specified PFA Index and lesion-spacing criteria were associated with 84.6% freedom from AF, atrial flutter or atrial tachycardia under stricter 12-month monitoring.
That finding remains retrospective and should not be interpreted as proof that using the index causes better outcomes. It nevertheless points toward an important competitive direction: PFA systems may increasingly differentiate not simply through catheters but through software-guided reproducibility.
Does lesion durability remain an unresolved PFA question?
Among 15 FlexPulse patients who underwent repeat ablation after the blanking period, investigators remapped 59 pulmonary veins and found that approximately 79.7% remained durably isolated.
That is useful information because acute electrical isolation does not guarantee a lesion will remain permanently effective. Reconnection can allow arrhythmia to recur and may lead to additional procedures.
A roughly 80% durable-isolation rate across remapped veins is encouraging but also indicates room for improvement. The sample is small and enriched for patients returning for repeat procedures, so it cannot be generalized directly to every treated patient. Continued refinement of lesion placement, energy dose and mapping feedback may therefore be central to the next generation of PFA systems.
How crowded is Abbott’s competitive landscape?
Pulsed-field ablation has quickly become one of the most contested medtech markets in electrophysiology. Medtronic markets PulseSelect, Boston Scientific built a significant position through FARAPULSE, and Johnson & Johnson has pursued its own PFA platforms alongside its established CARTO mapping franchise.
These companies are not merely selling catheters. Each is building an ecosystem involving mapping, imaging, generators, workflow software and disposable devices. Hospitals may therefore evaluate platforms based partly on installed infrastructure and physician familiarity rather than isolated clinical specifications.
Abbott’s advantage is breadth. It participates across mapping, contact-force sensing, intracardiac imaging, radiofrequency ablation and PFA, allowing TactiFlex Duo to sit within an existing procedural environment rather than requiring an entirely separate workflow.
What does the FDA approval mean for Abbott Laboratories commercially?
Abbott Laboratories is diversified across medical devices, diagnostics, nutrition and established pharmaceuticals, so one catheter approval will not materially determine the company’s overall financial trajectory. Within electrophysiology, however, the launch strengthens Abbott’s ability to compete for procedural share as hospitals increasingly transition toward PFA.
Ablation businesses also create recurring disposable revenue. Once a hospital adopts an electrophysiology platform and physicians become comfortable with its mapping and catheter workflow, switching suppliers can involve training, capital equipment and changes to established procedures.
That makes portfolio breadth commercially valuable. A hospital using EnSite X may view TactiFlex Duo differently from one that would need to adopt an entirely new mapping environment, while clinicians already familiar with Abbott’s TactiFlex RF technology may find the transition to a related dual-energy catheter relatively intuitive.
Is dual energy the future or a transitional technology?
The answer may depend on what PFA eventually proves capable of doing. If non-thermal ablation ultimately handles most clinically relevant atrial targets safely and durably, the need for RF inside the same catheter could diminish.
If certain anatomies or arrhythmia mechanisms continue to benefit from thermal lesion characteristics, however, dual-energy systems could become particularly valuable in complex and repeat procedures. Abbott is effectively avoiding the need to predict one universal winner by giving physicians both tools.
The FlexPulse results show that the approach can deliver favourable safety and one-year effectiveness in paroxysmal AF. FDA approval now moves the test from a controlled clinical study into everyday electrophysiology laboratories.
The central question is therefore larger than whether TactiFlex Duo works. Pulsed-field ablation has already demonstrated enough value to reshape the market. Abbott Laboratories is betting that the next competitive advantage will come from making PFA more flexible, more measurable and more deeply integrated with existing electrophysiology workflows rather than simply making radiofrequency disappear.
